Planned Parenthood miscoding claim prompts watchdog’s call for federal inquiry
Do No Harm, a nonprofit opposing identity politics in medicine, has requested an HHS inspector general investigation into Planned Parenthood’s coding practices, alleging that visits for youth hormone prescriptions are misclassified to appear routine. The letter cites data indicating that between 2015 and 2025, Planned Parenthood affiliates wrote over 1,100 prescriptions for gender dysphoria while potentially using incorrect diagnosis codes, possibly enabling insurers to cover treatments that might otherwise be excluded. The group argues that such coding practices could conceal “sex‑rejecting” services, expose patients to significant risks, and allow private and public insurers to reimburse for medically unnecessary procedures. The article places the issue in the broader context of recent U.S. actions, including the Trump executive order ending federal support for gender transition care for minors and settlements by NYU Langone and UPMC to halt pediatric gender‑affirming interventions.
5 days ago
Do No Harm has asked the federal Health and Human Services inspector general to investigate whether Planned Parenthood affiliates used inaccurate diagnosis codes in connection with hormone prescriptions for minors. The allegation is based on an outside data review described in the group’s letter; the articles report no finding that Planned Parenthood committed wrongdoing. 1 2
In a Sept. 22 letter, Do No Harm alleged that coding practices may make visits associated with youth cross-sex hormone prescriptions appear routine, potentially allowing insurers to cover treatments that might otherwise be excluded. The group contends that this could result in improper reimbursement, including from government programs, which it says cover only medically necessary care. 1 2
The group asked the inspector general to examine Planned Parenthood’s office-visit coding and determine whether those visits led to pharmacies filling hormone prescriptions that were submitted for federal reimbursement. Do No Harm said a private investigation could not establish the full picture without government investigative tools. 1 2
The letter says a professional data broker reviewed Planned Parenthood coding from 2015 to 2025 and identified about 800 patients nationwide associated with roughly 1,100 to 1,200 prescriptions that appeared related to gender dysphoria. Do No Harm said the affiliates may not have used the correct diagnosis codes for the associated visits; the articles describe this as the group’s finding, not as an independently confirmed determination. 1 2
Do No Harm also cited what it characterized as discussions by some Planned Parenthood affiliates and the World Professional Association for Transgender Health about strategic coding. The group raised concerns about treatment risks and the quality of evidence on safety and effectiveness, and asserted that the services can create long-term patients. 1 2
The request follows a Sept. 18 announcement that New York University Langone Hospitals and the University of Pittsburgh Medical Center agreed to stop pediatric gender-affirming medical interventions for minors and pay penalties to resolve Justice Department investigations. NYU Langone agreed to pay $8.5 million and UPMC $950,000. 1 2
The articles also note a January executive order by President Donald Trump ending federal support for gender-transition-related care for minors, and an August HHS report that referred clinics and hospitals to the Justice Department and inspector general for possible investigations. Planned Parenthood did not respond to the article’s request for comment. 1 2
Catholic bioethics evaluates pediatric gender-transition medicine
Catholic bioethics judges pediatric gender-transition medicine by whether it respects the child’s bodily integrity and the unity of body and person—not simply by whether an intervention is intended to relieve distress. The 2023 doctrinal note of the U.S. bishops rejects chemical or surgical interventions intended to transform a person’s sexual characteristics toward those of the opposite sex. It specifically identifies puberty blockers as drugs that arrest the natural course of puberty and prevent some sex characteristics from developing.
The note also emphasizes special care for children and adolescents, who are still maturing and, it says, are not capable of providing informed consent. Catholic health care, it teaches, should use appropriate means to mitigate the suffering associated with gender incongruence, while respecting the fundamental order of the human body. This rules out treating a child’s distress as grounds for interventions that aim to alter sexual characteristics; it does not mean the child’s distress should be ignored.
The reasoning is rooted in a Catholic view of the person as an embodied unity: the body is not merely material to reshape according to an individual’s sense of identity. A scholarly Catholic bioethics article similarly argues that transition-related procedures do not change a person’s biological sex, while noting that they are intended to make bodily appearance correspond more closely to experienced gender identity.
There has been theological debate about some surgical interventions in adults and whether the principle of totality—the idea that bodily parts may sometimes be sacrificed for the good of the whole person—could apply in exceptional cases. One scholarly account describes that as a minority position and notes significant disagreement among Catholic moralists. That debate does not overturn the bishops’ doctrinal guidance for Catholic health-care services, which says they must not perform or assist interventions intended to transform sexual characteristics.
In short, this Catholic assessment opposes pediatric puberty suppression and other medical interventions directed toward gender transition, while insisting that young people experiencing distress be treated with dignity and receive appropriate support by morally acceptable means.